

Serum Galectin-3 as a Non-Invasive Marker for Primary Sclerosing Cholangitis

Ganimete Bajraktari, Tanja Elger, Muriel Huss, Johanna Loibl, Andreas Albert, Arne Kandulski, Martina Müller, Hauke Christian Tews and Christa Buechler *




Figure S1. Schematic summary of the effect of dextran sodium sulfate in the gut and the liver.




Figure S2. Serum and urinary galectin-3 (Gal3) of patients with inflammatory bowel disease who did develop tumors during therapy in comparison to patients who did not have tumors. (a) Serum Gal3; (b) Urinary Gal3.